Skip to main content

ADVERTISEMENT

Melanoma

06/10/2016
JCP Editors
Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at...
Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at...
...
06/10/2016
Journal of Clinical Pathways
Department
06/06/2016
JCP Editors
Patients with advanced melanoma treated with a Programmed cell death protein-1 (PD-1) immune checkpoint inhibitor have longer survival than historically treated patients, according to results from a phase 1 clinical...
Patients with advanced melanoma treated with a Programmed cell death protein-1 (PD-1) immune checkpoint inhibitor have longer survival than historically treated patients, according to results from a phase 1 clinical...
...
06/06/2016
Journal of Clinical Pathways
News
12/10/2015
PORTLAND, Ore. – Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular value with cancers like this...
PORTLAND, Ore. – Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular value with cancers like this...
PORTLAND, Ore. – Researchers...
12/10/2015
IO Learning
News
10/28/2015
The Melanoma Research Alliance (MRA) welcomes another exciting new chapter in the treatment of melanoma with the news that the US Food & Drug Administration (FDA) has given approval to Amgen’s immunotherapy drug, IMLYGIC, known as T-VEC for...
The Melanoma Research Alliance (MRA) welcomes another exciting new chapter in the treatment of melanoma with the news that the US Food & Drug Administration (FDA) has given approval to Amgen’s immunotherapy drug, IMLYGIC, known as T-VEC for...
The Melanoma Research Alliance...
10/28/2015
IO Learning